Tvardi Therapeutics, Inc.
Cash Flow Statement
| Line Item | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 |
|---|---|---|---|---|---|---|
| Operating Activities | ||||||
| Net Income | $-58.1M | $-57.3M | $-24.7M | $-17.7M | $-4.0M | $-6.3M |
| Depreciation & Amortization | $495.0K | $1.5M | $839.0K | $783.0K | $789.0K | $1.0M |
| Depreciation | — | — | — | — | — | — |
| Amortization | — | — | — | — | — | — |
| Stock-Based Compensation | $5.8M | $2.8M | $2.5M | $1.4M | $123.0K | $61.0K |
| Net Cash from Operating Activities | $-54.8M | $-47.4M | $-21.5M | $-17.6M | $2.8M | $-6.0M |
| Investing Activities | ||||||
| Capital Expenditures | $58.0K | $717.0K | $20.0K | $42.0K | $5.0K | — |
| Business Acquisitions | — | — | — | — | — | — |
| Net Cash from Investing Activities | $-36.5M | $45.0M | — | — | — | — |
| Financing Activities | ||||||
| Dividends Paid | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — |
| Net Cash from Financing Activities | $87.9M | $123.0K | — | — | — | — |
| Net Change in Cash | $-2.7M | $-3.0M | $-37.6M | $40.3M | $11.2M | $-3.0M |
| Free Cash Flow | $-54.9M | $-48.1M | $-21.5M | $-17.7M | $2.8M | — |